143 related articles for article (PubMed ID: 19915829)
1. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.
Malhotra BK; Crownover PH; LaBadie R; Glue P; MacDiarmid SA
Eur J Clin Pharmacol; 2010 Feb; 66(2):171-6. PubMed ID: 19915829
[TBL] [Abstract][Full Text] [Related]
2. Influence of food on the pharmacokinetic profile of fesoterodine.
Malhotra B; Sachse R; Wood N
Int J Clin Pharmacol Ther; 2009 Jun; 47(6):384-90. PubMed ID: 19473600
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Malhotra B; Darsey E; Crownover P; Fang J; Glue P
Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
[TBL] [Abstract][Full Text] [Related]
4. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine.
de Mey C; Mateva L; Krastev Z; Sachse R; Wood N; Malhotra B
J Clin Pharmacol; 2011 Mar; 51(3):397-405. PubMed ID: 20371737
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Simon HU; Malhotra B
Swiss Med Wkly; 2009 Mar; 139(9-10):146-51. PubMed ID: 19145494
[TBL] [Abstract][Full Text] [Related]
6. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
Malhotra B; Dickins M; Alvey C; Jumadilova Z; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):263-9. PubMed ID: 21545485
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.
Oishi M; Tomono Y; Yamagami H; Malhotra B
J Clin Pharmacol; 2014 Aug; 54(8):928-36. PubMed ID: 24619889
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile of fesoterodine.
Malhotra B; Guan Z; Wood N; Gandelman K
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):556-63. PubMed ID: 19000553
[TBL] [Abstract][Full Text] [Related]
9. Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers.
Shin D; Shin KH; Lee S; Lim KS; Cho JY; Jang IJ; Shin SG; Yu KS
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):722-8. PubMed ID: 22853865
[TBL] [Abstract][Full Text] [Related]
10. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine.
Malhotra BK; Wood N; Sachse R
Int J Clin Pharmacol Ther; 2009 Sep; 47(9):570-8. PubMed ID: 19761716
[TBL] [Abstract][Full Text] [Related]
11. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
Malhotra B; Gandelman K; Sachse R; Wood N; Michel MC
Curr Med Chem; 2009; 16(33):4481-9. PubMed ID: 19835561
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
13. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
Olsson B; Szamosi J
Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
[TBL] [Abstract][Full Text] [Related]
14. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
[TBL] [Abstract][Full Text] [Related]
15. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
Rackley R; Weiss JP; Rovner ES; Wang JT; Guan Z;
Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine.
Malhotra B; Gandelman K; Sachse R; Wood N
J Clin Pharmacol; 2009 Apr; 49(4):477-82. PubMed ID: 19246724
[TBL] [Abstract][Full Text] [Related]
17. Food increases the bioavailability of tolterodine but not effective exposure.
Olsson B; Brynne N; Johansson C; Arnberg H
J Clin Pharmacol; 2001 Mar; 41(3):298-304. PubMed ID: 11269570
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of drug-drug interactions with fesoterodine.
Malhotra B; Sachse R; Wood N
Eur J Clin Pharmacol; 2009 Jun; 65(6):551-60. PubMed ID: 19347334
[TBL] [Abstract][Full Text] [Related]
19. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
20. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
